International Journal of Cardiology Cardiovascular Risk and Prevention最新文献

{"title":"Goal attainment, medication adherence and guideline adherence in the treatment of hypertension and dyslipidemia in Irish populations: A systematic review and meta-analysis","authors":"Rehab Elhiny ,&nbsp;Linda M. O'Keeffe ,&nbsp;Elizabeth O. Bodunde ,&nbsp;Stephen Byrne ,&nbsp;Maria Donovan ,&nbsp;Margaret Bermingham","doi":"10.1016/j.ijcrp.2025.200364","DOIUrl":"10.1016/j.ijcrp.2025.200364","url":null,"abstract":"<div><h3>Background</h3><div>The appropriate treatment high blood pressure (BP) and low-density lipoprotein cholesterol.</div><div>(LDL-C), according to clinical guidelines, reduces a patient's risk of a cardiovascular event.</div></div><div><h3>Aim</h3><div>This systematic review aims to evaluate the attainment of BP and LDL-C goals among the Irish population in both primary and secondary prevention of cardiovascular diseases, the level of adherence to prescribing guidelines by doctors and the level of medication adherence among patients.</div></div><div><h3>Methods</h3><div>Five databases were searched in March 2024. Quantitative articles reporting levels of goals attainment, medication adherence or guideline adherence for LDL-C and BP among Irish adults aged ≥18 years were included. The proportion of patients attaining their LDL-Cor BP goals were statistically combined using the random effect model.</div></div><div><h3>Results</h3><div>Following screening, 23 eligible articles were identified. The achievement of LDL-C &lt;1.8 mmol/L was 41 % (95 % CI 31,52), compared to 69 % of people (95 % CI 62,76) reported to have achieved the less stringent goal of LDL-C &lt; 3 mmol/L. The achievement of BP &lt; 140/90 mmHg was 56 % (95 % CI 46,65). Medication adherence levels ranged between 27 % and 92 %. Guideline adherence findings demonstrated that not all patients who should be on lipid-lowering therapy are and that choice of antihypertensive is not always in line with the guidelines.</div></div><div><h3>Conclusion</h3><div>Approximately one-third of deaths in Ireland annually are caused by cardiovascular disease, despite being preventable. There is room for improvement in goal attainments in people at risk of CVDs and optimization of medication adherence and guideline adherence may be beneficial in this population.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"24 ","pages":"Article 200364"},"PeriodicalIF":1.9,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143060888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is systolic blood pressure an early marker of concentric left ventricular geometry in young rugby athletes as a potential cardiac maladaptation?","authors":"Yoshitaka Iso ,&nbsp;Hitomi Kitai ,&nbsp;Megumi Kubota ,&nbsp;Miki Tsujiuchi ,&nbsp;Sakura Nagumo ,&nbsp;Tsutomu Toshida ,&nbsp;Mio Ebato ,&nbsp;Hiroshi Suzuki","doi":"10.1016/j.ijcrp.2024.200362","DOIUrl":"10.1016/j.ijcrp.2024.200362","url":null,"abstract":"<div><h3>Background</h3><div>Long-term exercise training induces various morphological adaptations in the heart. Although concentric left ventricular (LV) geometry is occasionally observed in young athletes, its clinical significance is unclear. This study aimed to investigate the characteristics of young rugby athletes with concentric LV geometry and considered its clinical implications.</div></div><div><h3>Methods and results</h3><div>This cross-sectional study assessed 120 male collegiate rugby freshmen, with a healthy lifestyle and without a family history, via physical and blood pressure evaluations, resting 12-lead electrocardiography (ECG), echocardiography, and cardiopulmonary exercise testing. The athletes were divided into three groups based on the 4-tiered echocardiographic classification for LV hypertrophy: normal geometry, concentric geometry, and eccentric hypertrophy. Concentric geometry was identified in 11 % of the athletes. No significant differences in anthropometry or exercise capacity were observed between athletes with normal and abnormal geometries. However, athletes with concentric geometry had significantly higher systolic blood pressure (SBP) compared to the other groups. SBP levels were significantly correlated with both LV mass index and concentricity; an SBP ≥136 mmHg could independently predict concentric geometry. In contrast, the ECG criteria for LV hypertrophy showed limited diagnostic accuracy for detecting concentric geometry.</div></div><div><h3>Conclusion</h3><div>These findings suggest that elevated SBP can serve as an early marker for identifying and managing concentric geometry in young athletes, which potentially represents a mild, previously unrecognized form of hypertensive remodeling.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"24 ","pages":"Article 200362"},"PeriodicalIF":1.9,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11741054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perivascular fat attenuation index (FAI) on computed tomography coronary angiography reclassifies individual cardiovascular risk estimation","authors":"Casper F. Coerkamp ,&nbsp;Victor A. Verpalen ,&nbsp;Remko S. Kuipers ,&nbsp;Annet Driessen-Waaijer ,&nbsp;Victor P.M. van der Hulst ,&nbsp;Nils R. Planken ,&nbsp;José P.S. Henriques ,&nbsp;Robert K. Riezebos","doi":"10.1016/j.ijcrp.2024.200360","DOIUrl":"10.1016/j.ijcrp.2024.200360","url":null,"abstract":"<div><h3>Background</h3><div>The perivascular fat attenuation index (FAI) detects and quantifies coronary inflammation by measuring phenotypic changes in perivascular adipose tissue by using computed tomography coronary angiography images.</div></div><div><h3>Aim</h3><div>The primary objective of this study was to evaluate the reclassification of cardiovascular (CV) risk after incorporating perivascular FAI assessment in currently used risk score algorithms.</div></div><div><h3>Methods</h3><div>This was a single-center, retrospective study of 200 patients with suspected coronary artery disease who underwent computed tomography coronary angiography in clinical practice between January 2022 and May 2022. From the patients who met the inclusion criteria, we included 50 patients with the highest CV risk according to the U-prevent calculator score to perform the perivascular FAI analysis. High perivascular FAI was defined as either a FAI-Score of ≥75th percentile in the left anterior descending artery or right coronary artery, or ≥95th percentile in the left circumflex artery.</div></div><div><h3>Results</h3><div>In 62 % of the patients, there was a reclassification in CV risk after perivascular FAI assessment; individual risk was upgraded in 22 % of patients and in 40 % their risk was downgraded. The presence of any plaque (72.7 % vs. 94.1 %; <em>P</em> = 0.032) and the proportion of patients with moderate-to-high coronary artery calcium score (≥100 Agatston units) was higher in the high perivascular FAI group compared to the low FAI group (76.5 % vs. 36.4 %; <em>P</em> = 0.016). Major adverse cardiac and cerebrovascular events did not differ between both groups.</div></div><div><h3>Conclusion</h3><div>The findings in this study suggest the potential valuable role of perivascular FAI assessment in individual CV risk prediction for patients with documented or suspected coronary artery disease.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"24 ","pages":"Article 200360"},"PeriodicalIF":1.9,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of chronic total occlusion of coronary arteries on cardiovascular outcomes in patients undergoing transcatheter aortic valve replacement: A systematic review and meta-analysis","authors":"Aman Goyal ,&nbsp;Muhammad Daoud Tariq ,&nbsp;Areeba Ahsan ,&nbsp;Sonia Hurjkaliani ,&nbsp;Ajeet Singh ,&nbsp;Hafiz Muhammad Hamza ,&nbsp;Hritvik Jain ,&nbsp;Hareesha Rishab Bharadwaj ,&nbsp;Mohamed Daoud ,&nbsp;Abu Baker Sheikh","doi":"10.1016/j.ijcrp.2024.200356","DOIUrl":"10.1016/j.ijcrp.2024.200356","url":null,"abstract":"<div><h3>Background</h3><div>Transcatheter aortic valve replacement (TAVR) has significantly advanced the treatment of severe aortic stenosis (AS), particularly in elderly patients who often have coexisting coronary artery disease (CAD). Chronic total occlusion (CTO), a severe form of CAD, may negatively impact outcomes in TAVR patients, though data are limited. This meta-analysis aims to evaluate the impact of CTO on TAVR outcomes.</div></div><div><h3>Methods</h3><div>A comprehensive literature search was conducted across multiple electronic databases to identify studies comparing TAVR outcomes in patients with and without CTO. Pooled risk ratios (RR) with 95 % confidence intervals (CIs) were calculated using a random-effects model. The primary outcome was all-cause mortality, with several secondary endpoints also assessed.</div></div><div><h3>Results</h3><div>Six studies involving a total of 331,159 TAVR patients were included in this meta-analysis. CTO was associated with a significantly increased risk of in-hospital mortality (RR: 1.24; 95 % CI: 1.01, 1.52; p = 0.04), acute myocardial infarction (RR: 1.67; 95 % CI: 1.48, 1.89; p &lt; 0.00001), acute kidney injury (RR: 1.46; 95 % CI: 1.37, 1.56; p &lt; 0.00001), and vascular complications (RR: 1.47; 95 % CI: 1.28, 1.69; p &lt; 0.00001). No significant differences were observed in all-cause mortality (RR: 1.21; 95 % CI: 0.76, 1.93; p = 0.42), stroke (RR: 1.09; 95 % CI: 0.91, 1.30; p = 0.37), or bleeding events (RR: 1.19; 95 % CI: 1.00, 1.41; p = 0.06).</div></div><div><h3>Conclusion</h3><div>CTO poses a significant risk in TAVR patients, particularly for in-hospital mortality and acute myocardial infarction. A multidisciplinary approach is recommended for these patients, with consideration given to revascularization before TAVR. Further studies are needed to evaluate the potential benefits of prior CTO-PCI.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"24 ","pages":"Article 200356"},"PeriodicalIF":1.9,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chest pain in a multi-ethnic population: A community-based study on sex differences in chest pain prevalence and care contacts","authors":"Bryn Hummel ,&nbsp;Ralf E. Harskamp ,&nbsp;Annick Vester ,&nbsp;Henrike Galenkamp ,&nbsp;Paula M.C. Mommersteeg ,&nbsp;Irene G.M. van Valkengoed ,&nbsp;the IMPRESS consortium","doi":"10.1016/j.ijcrp.2024.200361","DOIUrl":"10.1016/j.ijcrp.2024.200361","url":null,"abstract":"<div><h3>Objective</h3><div>While chest pain is a common symptom, its prevalence among women and men across ethnic groups is unknown. Moreover, how chest pain is associated with general practitioner (GP) and cardiologist visits in women and men across ethnic groups, remains to be determined.</div></div><div><h3>Design</h3><div>We used baseline data on 12423 women and 9071 men from the multi-ethnic HELIUS cohort (Amsterdam, the Netherlands; 2011–2015). Using logistic regressions, we studied sex differences in chest pain prevalence across ethnic groups. Next, in those who reported chest pain in the past two years (henceforth; recent chest pain), we studied sex differences in GP, cardiologist, and any specialists visits, in total and by ethnicity. Analyses were adjusted for age, ethnicity (in the total population), socioeconomic factors, associated symptoms, clinical parameters, and lifestyle factors.</div></div><div><h3>Results</h3><div>Across most ethnic groups, women were more likely than men to report lifetime (33 % vs 29 %, p &lt; .001) and recent chest pain (4.5 % vs 2.7 %, p = .001). In those with recent chest pain, women were more likely to have visited a GP, yet less likely to have visited a cardiologist, but not any specialist, compared to men. These differences were also observed in several sensitivity analyses, including in those with symptoms suggestive of typical Angina Pectoris.</div></div><div><h3>Conclusion</h3><div>Chest pain is more commonly reported in women than men across most ethnic groups. While men were less likely to have visited a GP than women, women were less likely to have visited a cardiologist. Combined, this suggests delays in care may occur at different points in the care trajectory for women and men.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"24 ","pages":"Article 200361"},"PeriodicalIF":1.9,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11728961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the beneficial effects of pemafibrate in hypertriglyceridemia with or without alcohol drinking (PAR-CHAT: PARmodia-CHikushi Anti-dyslipidemia Trial)","authors":"Yosuke Takamiya,&nbsp;Chiyori Imanaga,&nbsp;Amane Ike,&nbsp;Akira Kawamura,&nbsp;Hidenori Urata","doi":"10.1016/j.ijcrp.2024.200359","DOIUrl":"10.1016/j.ijcrp.2024.200359","url":null,"abstract":"<div><h3>Purpose</h3><div>To examine the efficacy and safety of pemafibrate in outpatients with hypertriglyceridemia, including alcoholic hypertriglyceridemia.</div></div><div><h3>Method</h3><div>This multicenter, open-label, prospective observational study (C20-07-009) included outpatients with hypertriglyceridemia being treated with pemafibrate who were registered at Fukuoka University Chikushi Hospital or associated clinics. Endpoints were changes in serum triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C), hepatic biomarkers, and other blood values from baseline to 24 weeks and safety. Patients were compared according to alcohol drinking.</div></div><div><h3>Result</h3><div>From October 2020 to March 2022, 203 patients were registered at 14 facilities. We analyzed 174 patients (mean age, 65.5 years) with baseline fasting TG values who continued pemafibrate for 24 weeks; 55 % drank alcohol, and 35 % were receiving statins. Median fasting TG was 284 mg/dL (IQR, 228–392 mg/dL) at baseline and decreased significantly to 141 mg/dL (IQR, 108–194 mg/dL) at 24 weeks (p &lt; 0.01), independent of alcohol use (non-drinking group, 259 to 134 mg/dL; daily drinking group, 318 to 169 mg/dL; occasional drinking group, 298 to 158 mg/dL; all p &lt; 0.01). Median HDL-C increased significantly from 46 mg/dL (IQR, 39–53 mg/dL) at baseline to 53 mg/dL (IQR, 45–60 mg/dL) at 24 weeks (p &lt; 0.01). Hepatic biomarkers improved significantly at 24 weeks. Low-density lipoprotein cholesterol (LDL-C) increased significantly overall, but not in patients receiving statins. Side effects throughout the study period included dizziness and nausea (1 patient each).</div></div><div><h3>Conclusion</h3><div>Pemafibrate improves TG, HDL-C, hepatic biomarkers and hypertriglyceridemia regardless of alcohol consumption and is safe. Increase of LDL-C was suppressed in patients treated with statins.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"24 ","pages":"Article 200359"},"PeriodicalIF":1.9,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11719332/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measuring health-related quality of life in cardiovascular disease using a novel patient-centred and disease-specific patient-reported outcome measure","authors":"Tajinder K. Singh ,&nbsp;Daan Ties ,&nbsp;Hilde E. Groot ,&nbsp;Paul F.M. Krabbe ,&nbsp;Pim van der Harst","doi":"10.1016/j.ijcrp.2024.200357","DOIUrl":"10.1016/j.ijcrp.2024.200357","url":null,"abstract":"<div><h3>Background</h3><div>Assessment of health-related quality of life (HRQoL) in patients with cardiovascular disease (CVD) is impaired by limitations of current patient-reported outcome measures (PROMs). We developed the first cardiovascular disease (CVD) specific electronic PROM for which health items were derived by a fully patient-centered method. This paper reports on the measurement of HRQoL in CVD patients by a novel developed electronic patient-centred PROM based on a preference-based measurement model.</div></div><div><h3>Methods and results</h3><div>In an earlier patient-based study nine health items were selected as most important to CVD patients. These items were assessed in the novel preference-based PROM of this study. CVD patients registered with a Dutch patient organization were asked to rate their health state. We compared HRQoL between subgroups of age, gender and CVD. A total of 554 patients participated in this study. The patient reported health items “worry”, “self-reliance” and “sexuality” had the highest impact on HRQoL of CVD patients. Median HRQoL was better for men compared to woman (−17.04, IQR: 31.47 to −3.91 vs. −25.22; IQR: 42.06 to −9.53, p = 0.003). Best and worst HRQoL were observed in patients with an unknown or other CVD disease (−15.61, IQR: 28.52 to −3.91) followed by individuals with coronary artery disease (−16.99, IQR: 38.08 - 0.00) and heart failure (−24.27, IQR: 42.64 to −12.98).</div></div><div><h3>Conclusions</h3><div>This novel patient-centred, preference-based, CVD-specific PROM accurately measures HRQoL by taking individual health preferences into account and tackling limitations of current PROMs. This PROM is therefore promising to evaluate interventions and optimize personalized therapies.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"24 ","pages":"Article 200357"},"PeriodicalIF":1.9,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of antihypertensives with and without IL-6 lowering properties on long-term blood pressure control: The prospective HELIUS cohort","authors":"Hillmann Batuo ,&nbsp;Eva van der Linden ,&nbsp;Henrike Galenkamp ,&nbsp;Eric Moll van Charante ,&nbsp;Bert-Jan van der Born ,&nbsp;Felix P. Chilunga","doi":"10.1016/j.ijcrp.2024.200358","DOIUrl":"10.1016/j.ijcrp.2024.200358","url":null,"abstract":"<div><h3>Background</h3><div>Chronic inflammation is a well-recognized contributor to hypertension pathogenesis. However, the role of targeting inflammation in hypertension treatment, particularly through modulation of inflammatory markers like interleukin-6 (IL-6), remains less understood. We investigated the effects of antihypertensive medications with and without IL-6-lowering properties on long-term blood pressure (BP) control in a multi-ethnic cohort in the Netherlands.</div></div><div><h3>Methods</h3><div>Participants from HELIUS cohort receiving hypertension treatment were followed over six years. BP control at follow-up was determined using WHO criteria. Due to unavailability of IL-6 data, a literature review was conducted to classify antihypertensives based on their IL-6-lowering properties — a proxy approach. Logistic regression models were used to assess associations between the IL-6-lowering potential of antihypertensives and BP control, both within and between antihypertensive classes. Effect modification by ethnicity was explored.</div></div><div><h3>Results</h3><div>A total of 1510 participants were included (mean age 57 years, 62 % women). Within the calcium channel blocker (CCB) class, medications with IL-6-lowering properties (amlodipine and barnidipine) were associated with superior BP control (aOR 1.41, 95 % confidence interval 1.05–1.90) compared to other CCBs (lercanidipine, nifedipine, verapamil, clevidipine, diltiazem). No significant associations were observed within angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs), between different antihypertensive drug classes, nor across ethnic groups.</div></div><div><h3>Conclusion</h3><div>Amlodipine and barnidipine were associated with better BP control compared to other CCBs. Our findings provide an important starting point for understanding the role of IL-6 in hypertension management. Further studies are warranted to confirm these observations by directly measuring IL-6 levels and investigating underlying mechanisms.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"24 ","pages":"Article 200358"},"PeriodicalIF":1.9,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal associations between hypertension and abnormal brain cortical structures: Insights from a bidirectional Mendelian randomization study","authors":"Tianxiang Fang ,&nbsp;Xizhi Wang ,&nbsp;Yingsong Wang ,&nbsp;Xiaoya Zheng ,&nbsp;Ning Huangfu","doi":"10.1016/j.ijcrp.2024.200354","DOIUrl":"10.1016/j.ijcrp.2024.200354","url":null,"abstract":"<div><h3>Background</h3><div>Observational studies suggest that hypertension affects brain cortical structure. However, the potential causal association has yet to be entirely determined. Thus, we aim to assess the causality between hypertension and abnormal cortical structure.</div></div><div><h3>Methods</h3><div>We conducted a bidirectional Mendelian randomization (MR) study to estimate their relationship. Genome-wide association study summary statistics of hypertension (n = 484,598) and brain cortical (surface area and thickness) (n = 51,665) were derived from publicly available databases. Sensitivity analyses were applied to ensure the robustness of the results.</div></div><div><h3>Results</h3><div>The study showed that hypertension was associated with a decline in total brain cortical thickness [β, -0.0308 mm; 95 % confidence interval (CI), -0.0610 to -0.0007; <em>p</em> = 0.045] and the insula thickness [β, -0.0415 mm; 95 % CI, -0.0772 to -0.0057; <em>p</em> = 0.023]. A null association was observed between hypertension and other brain regions. In the reverse MR analysis, the total cortical surface area (per 1 SD increase) significantly decreased the incidence of hypertension [odds ratio (OR), 0.976; 95 % CI, 0.963 to 0.990; <em>p</em> = 5.15E-04]. The caudal anterior cingulate cortex thickness (per 1 SD increase) was significantly associated with an increased risk of hypertension [OR, 1.057; 95 % CI, 1.034 to 1.082; <em>p</em> = 1.08E-06]. Moreover, we found several nominally associated gyri, including cuneus, isthmus cingulate, middle temporal, para hippocampal, posterior cingulate, superior temporal, and medial orbitofrontal, influence the incidence of hypertension.</div></div><div><h3>Conclusion</h3><div>Our study showed causal relationships between hypertension and changes in specific brain cortical, providing new evidence for the heart-brain axis theory.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"24 ","pages":"Article 200354"},"PeriodicalIF":1.9,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of miR-155 in cardiovascular diseases: Potential diagnostic and therapeutic targets","authors":"Rui-Lin Zhang ,&nbsp;Wei-Ming Wang ,&nbsp;Ji-Qiang Li ,&nbsp;Run-Wen Li ,&nbsp;Jie Zhang ,&nbsp;Ya Wu ,&nbsp;Yong Liu","doi":"10.1016/j.ijcrp.2024.200355","DOIUrl":"10.1016/j.ijcrp.2024.200355","url":null,"abstract":"<div><div>Cardiovascular diseases (CVDs), such as atherosclerotic cardiovascular diseases, heart failure (HF), and acute coronary syndrome, represent a significant threat to global health and impose considerable socioeconomic burdens. The intricate pathogenesis of CVD involves various regulatory mechanisms, among which microRNAs (miRNAs) have emerged as critical posttranscriptional regulators. In particular, miR-155 has demonstrated differential expression patterns across a spectrum of CVD and is implicated in the etiology and progression of arterial disorders. This systematic review synthesizes current evidence on the multifaceted roles of miR-155 in the modulation of genes and pathological processes associated with CVD. We delineate the potential of miR-155 as a diagnostic biomarker and therapeutic target, highlighting its significant regulatory influence on conditions such as atherosclerosis, aneurysm, hypertension, HF, myocardial hypertrophy, and oxidative stress. Our analysis underscores the transformative potential of miR-155 as a target for intervention in cardiovascular medicine, warranting further investigation into its clinical applicability.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"24 ","pages":"Article 200355"},"PeriodicalIF":1.9,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}